EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications

Yuanxun Yue iD, Zhizhong Ren iD, Yaqin Wang, Ying Liu, Xiaowei Yang, Tianxiao Wang, Yating Bai, He Zhou, Qian Chen, Sujun Li, Yuewei Zhang iD

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.70007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Yuanxun Yue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional and Pain, Beijing Luhe Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Myeloid-Derived Suppressor Cells, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Tsinghua Precision Medicine Foundation, Capital's Funds for Health Improvement and Research, The Major Science and Technology R&D Project of the Science and Technology Department of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myeloid‐derived suppressor cells (MDSCs) play a pivotal role in immunosuppression and tumor progression in hepatocellular carcinoma (HCC). While various treatments like surgical resection, ablation, and radiotherapy have been studied for their effects on circulating MDSC frequencies in HCC patients, the findings remain inconclusive. Transarterial Chemoembolization (TACE) stands as the standard care for unresectable HCC, with Microparticle TACE (mTACE) gaining prominence for its capacity to induce significant tumor necrosis. However, the immunological ramifications of such pathological outcomes are scarcely reported. Methods and Results This study aims to elucidate the alterations in MDSC subtypes, specifically monocytic MDSCs (mMDSCs) and early‐stage MDSCs (eMDSCs), post‐mTACE and to investigate their clinical correlations in HCC patients. A cohort comprising 75 HCC patients, 16 liver cirrhosis patients, and 20 healthy controls (HC) was studied. Peripheral blood samples were collected and analyzed for MDSC subtypes. The study also explored the associations between MDSC frequencies and various clinical parameters in HCC patients. The frequency of mMDSCs was significantly elevated in the HCC group compared to liver cirrhosis and HC. Importantly, mMDSC levels were strongly correlated with aggressive clinical features of HCC, including tumor size, vascular invasion, and distant metastasis. Post‐mTACE, a marked reduction in mMDSC frequencies was observed, while eMDSC levels remained stable.

Conclusions

Our findings underscore the critical role of mMDSCs in HCC pathogenesis and their potential as a therapeutic target. The study also highlights the efficacy of mTACE in modulating the immunosuppressive tumor microenvironment, thereby opening new avenues for combinatorial immunotherapeutic strategies in HCC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMyeloid-Derived Suppressor CellsChemoembolization, TherapeuticHumansMaleFemaleMiddle AgedAgedCell-Derived MicroparticlesAdultTumor Microenvironment

Stichwörter der Autor:innen

Transarterial Chemoembolization (TACE)early stage MDSCsgelatin sponge microparticles (GSMs)hepatocellular carcinoma (HCC)monocytic‐myeloid‐derived suppressor cells (mMDSCs)

Autor:innen und Institutionen

  • Department of Interventional and Pain, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Hepatobiliary Interventional Department, Beijing Tsinghua Chang Gung Hospital Affiliated to Tsinghua University, Beijing, China.
  • Thorgene Co., Ltd., Beijing, China.
  • Shanghai Dengding BioAI Co., Shanghai, China.
  • Translational Medicine Institute of Jiangxi, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • JiangXi Key Laboratory of Transfusion Medicine, Nanchang, China.

ORCID-Profile: Yuanxun Yue, Zhizhong Ren, Yuewei Zhang

Förderung

  • The Tsinghua Precision Medicine Foundation
  • Capital's Funds for Health Improvement and Research
  • The Major Science and Technology R&D Project of the Science and Technology Department of Jiangxi Province

Zitieren

APA

Yue, Y., Ren, Z., Wang, Y., Liu, Y., Yang, X., Wang, T., Bai, Y., Zhou, H., Chen, Q., Li, S., & Zhang, Y. (2024). Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70007

Vancouver

Yue Y, Ren Z, Wang Y, Liu Y, Yang X, Wang T, et al. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70007

BibTeX
@article{Yue2024,
  author = {Yue, Yuanxun and Ren, Zhizhong and Wang, Yaqin and Liu, Ying and Yang, Xiaowei and Wang, Tianxiao and Bai, Yating and Zhou, He and Chen, Qian and Li, Sujun and Zhang, Yuewei},
  title = {Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid‐derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.70007}
}
Kostenlos starten →